Phase 4 N=30 Mechanisms of Weight Loss With SGLT2 Inhibition
Type 2 Diabetes · Overweight · Obesity
Primary: Change in Body Weight — 3.0; 0.3 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=41 Comparative Study of Two Different Techniques to Perform TAP-blocks
POSTOPERATIVE PAIN
Primary: Time Taken to Perform the Block — 2.4; 12.1 minutes — p=<0.001
Phase 4 N=120 Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)
Influenza
Primary: Number of Participants With Seroprotection to Influenza Vaccine Antigens at Day 0 (Pre-vaccination) and Day 21 (Post-vaccination) — 41; 37; 60; 60 Participants
Phase 4 N=102 Use of Santyl in Diabetic Foot Ulcers
Diabetic Foot · Foot Ulcer, Diabetic
Primary: Mean Percent Change in Ulcer Area From Baseline to the End of the Treatment. — 57.6; 41.3 percentage of change from baseline (cm2)
Phase 4 N=323 A Randomized Study of Three Medication Regimens for Acute Low Back Pain
Acute Low Back Pain
Primary: Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire — 5; 4; 7 units on a scale
Phase 4 N=200 SMART China, A Multi-center Clinical Registry Study
Atrial Fibrillation
Primary: Percentage of Patients With Freedom From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes — 80.7 Percentage of…
Phase 4 N=50 Switch to Unboosted Atazanavir With Tenofovir Study
HIV Infection
Primary: Proportions of Subjects Experiencing Virologic Failure by Randomized Treatment Arm — 2; 6 Participants
Phase 4 N=51 Phase IV O2 Consumption Study in COPD Patients.
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Oxygen Consumption (VO2; Obtained Via a Metabolic Cart) — 11.366; 1.252 mL/min — p=0.007
Phase 4 N=181 Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea
Nausea · Vomiting
Primary: Complete Response Rates Among Standard of Care and Combination Therapy Groups. — 58; 73; 31; 17 Participants — p=<.001
Phase 4 N=26 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
Exudative Macular Degeneration
Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 4 N=37 Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
Type II Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.0003; -0.0030; -0.0275 percentage of glycosylated hemoglobin
Phase 4 N=62 Citicoline for Alcohol Dependence
Alcohol Dependence
Primary: Heavy Drinking Days Per Week — 0.23; 0.33 days/week
Phase 4 N=120 Multimodal Pain Management for Cesarean Delivery
Pain
Primary: Total Opioid Intake in Morphine Milligram Equivalents in the First 48 Hours After Cesarean Delivery (CD) — 42; 49.5 morphine milligram equivalents
Phase 4 N=102 Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Multiple Sclerosis
Primary: Percentage of Participants With a Worsening in Severity of Gastrointestinal (GI) Adverse Events (AEs) on the GSRS From Day 0 to Day 10 — 17; 33 percentage of…